American Heart Journal
Volume 151, Issue 4 , Pages 765-767 , April 2006

Unraveling the pathophysiology of acute heart failure: An inflammatory proposal

  • G. Michael Felker, MD, MHS

      Affiliations

    • Corresponding Author InformationReprint requests: G. Michael Felker, MD, MHS, Duke Clinical Research Institute, 2400 Pratt St, Rm 0311 Terrace Level, Durham, NC 27710.
    • ,
  • Gadi Cotter, MD

References 

  1. Felker GM, Adams KF, Konstam MA, et al. The problem of decompensated heart failure: nomenclature, classification, and risk stratification. Am Heart J. 2003;145:S18–S25
  2. DeWood MA, Spores J, Notske R, et al. Prevalence of total coronary occlusion during the early hours of transmural myocardial infarction. N Engl J Med. 1980;303:897–902
  3. The PURSUIT Trial Investigators . Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. N Engl J Med. 1998;339:436–443
  4. The GUSTO Investigators . An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med. 1993;329:673–682
  5. Ramirez A, Abelmann WH. Cardiac decompensation. N Engl J Med. 1974;290:499–501
  6. Michalsen A, Konig GTW. Preventable causative factors leading to hospital admission with decompensated heart failure. Heart. 1998;80:437–441
  7. Opasich C, Febo O, Riccardi PG, et al. Concomitant factors of decompensation in chronic heart failure. Am J Cardiol. 1996;78:354–357
  8. Ghali JK, Kadakia S, Cooper R, et al. Precipitating factors leading to decompensation of heart failure: traits among urban blacks. Arch Intern Med. 1988;148:2013–2016
  9. Mann DL. Inflammatory mediators and the failing heart: past, present, and the foreseeable future. Circ Res. 2002;91:988–998
  10. Chung ESM. Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-[alpha], in patients with moderate-to-severe heart failure: results of the Anti-TNF Therapy Against Congestive Heart failure (ATTACH) Trial. Circulation. 2003;107:3133–3140
  11. Mann DL, McMurray JJV, Packer M, et al. Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL). Circulation. 2004;109:1594–1602
  12. Mann DL. Targeted anticytokine therapy and the failing heart. Am J Cardiol. 2005;95:9–16
  13. Conraads VM, Jorens PG, De Clerck LS, et al. Selective intestinal decontamination in advanced chronic heart failure: a pilot trial. Eur J Heart Fail. 2004;6:483–491
  14. Peschel T, Schonauer M, Thiele H, et al. Invasive assessment of bacterial endotoxin and inflammatory cytokines in patients with acute heart failure. Eur J Heart Fail. 2003;5:609–614
  15. Pagani FD, Baker LS, Hsi C, et al. Left ventricular systolic and diastolic dysfunction after infusion of tumor necrosis factor-alpha in conscious dogs. J Clin Invest. 1992;90:389–398
  16. Janssen SPM, Gayan-Ramirez G, Van Den Bergh A, et al. Interleukin-6 causes myocardial failure and skeletal muscle atrophy in rats. Circulation. 2005;111:996–1005
  17. Milo O, Cotter G, Kaluski E, et al. Comparison of inflammatory and neurohormonal activation in cardiogenic pulmonary edema secondary to ischemic versus nonischemic causes. Am J Cardiol. 2003;92:222–226
  18. Sabatine MS, Morrow DA, de Lemos JA, et al. Multimarker approach to risk stratification in non–ST elevation acute coronary syndromes: simultaneous assessment of troponin I. C-reactive protein, and B-type natriuretic peptide. Circulation. 2002;105:1760–1763
  19. Logeart D, Thabut G, Jourdain P, et al. Predischarge B-type natriuretic peptide assay for identifying patients at high risk of re-admission after decompensated heart failure. J Am Coll Cardiol. 2004;43:635–641

PII: S0002-8703(05)00722-2

doi: 10.1016/j.ahj.2005.07.004

American Heart Journal
Volume 151, Issue 4 , Pages 765-767 , April 2006

Article Tools